Details

Autor(en) / Beteiligte

• Aboagye, Eric O.
• Price, Patricia M.
• Padhani, A.R.

Titel

13 - Imaging of Pharmacodynamic End Points in Clinical Trials

Ist Teil von

• Novel Anticancer Agents, 2006, p.299,XVI-336,XX

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2006

Link zum Volltext

Beschreibungen/Notizen

• This chapter describes the application of noninvasive imaging methods positron emission tomography (PET) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for the pharmacodynamic evaluation of existing and new cancer therapeutics. PET methodology is being developed to enable evaluation of pathophysiology and pharmacodynamics in oncology. The high sensitivity and specificity of PET assays allow the mechanism of drug action to be assessed in patients. DCE-MRI is one of a number of MRI techniques that evaluates tumors with respect to their state of angiogenesis. There are a number of requirements that need to be met before DCE-MRI techniques can become mainstream diagnostic tools. Requirements include agreed protocols for data acquisition, analysis, and presentation methods. Appropriate imaging processing and visualization tools are needed to achieve this. The image acquisition techniques that are able to sample the whole tumor volume are also needed, particularly if the technique is to be extended to organs with significant physiological motion. It is suggested that macromolecular contrast enhanced MRI may become the preferred choice for these evaluations.